ADRM1 and ovarian carcinoma: In conclusion, we have sought to make more potent RPN13 inhibitors utilizing a rational development approach to judiciously modify substituents around the core unit of RA190 and, after several rounds of this, RA375 emerged as a promising compound based on pharmacodynamics and its reduction of tumor burden and prolongation of the survival of mice carrying an orthotopic human ovarian cancer xenograft.